Publications


Publications, Projects & Awards

Organized by program & group, as selected by each corresponding VHIO Principal Investigator

Please click on the corresponding programs below

Experimental Therapeutics Group

Imagen

Principal Investigator
Violeta Serra

Medical Oncologists
Cristina Cruz
Jordi Rodón

Post-Doctoral Fellows
Albert Gris-Oliver
Alba Llop-Guevara
Marta Palafox

Masters Student
Laia Monserrat

Graduate Students
Marta Castroviejo-Bermejo
Judith Llena
Mònica Sánchez-Guixé

ESMO Translational Research Fellow
Benedetta Pellegrino

Technicians
Judit Grueso
Marta Guzmán
Mireia Parés
Olga Rodríguez

PUBLICATIONS

  1. Méndez-Pertuz M, Martínez P, Blanco-Aparicio C, Gómez-Casero E, Belen García A, Martínez-Torrecuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA. Modulation of telomere protection by the PI3K/AKT pathway. Nat Commun. 2017 Nov 2;8(1):1278.
  2. Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, (…), Serra V, (…), Carracedo A. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017 Jul 6;547(7661):109-113.
  3. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? Hierro C, Alsina M, Sánchez M, Serra V, Rodon J, Tabernero J. Annals of Oncology. 2017 Jun 1;28(6):1207-1216.
  4. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E.  Stem Cell Reports. 2017 May 9;8(5):1392-1407.
  5. Interrogating open issues in cancer precision medicine with Patient-Derived Xenografts. Byrne et al (41 authors including Serra V). Nat Rev Cancer. 2017 Apr; 17(4):254-268.
  6. Lim E, Johnson SF, Geyer M, Serra V, Shapiro GI. Sensitizing HR-proficient cancers to PARP inhibitors. Mol Cell Oncol. 2017 Mar 3;4(6):e1299272.

PROJECTS

  • Project Title: Targeted agents against PARP, WEE1, ATR and ATM in TNBC: mechanisms of action, biomarkers of sensitivity and immunomodulation(PI17/01080).
    Principal Investigator: Violeta Serra
    Funding Agency: ISCIII
    Duration: 2018-2020
  • Project Title: New predictive factors of response to targeted therapies and prognostic factors in breast cancer with germline mutations in BRCA1 and BRCA2: DNA damage repair capacity and tumor immunological profile(LABAE16020PORT).
    Principal Investigator: Violeta Serra
    Funding Agency: AECC (Spanish Association Against Cancer)
    Duration: 2018-2020
  • Project Title: Targeting PI3K and CDK4/6 in breast cancer: Integrative Biomarkers of Response (CCR15330331).
    Principal Investigator: Violeta Serra
    Funding Agency: Susan G. Komen Foundation
    Duration: 2015-2018
  • Project Title: Targeting PI3K and CDK4/6 in breast cancer (CP14/00028).
    Principal Investigator: Violeta Serra
    Funding Agency: ISCIII (Spanish Ministry of Health)
    Duration: 2015-2019
  • Project Title: Clinical utility of tumor heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response (TH4RESPONS).
    Research Partner PI: Violeta Serra. Consortium coordinator: Manfred Dietel
    Funding Agency: ERA-NET
    Duration: 2016-2019
  • Project Title: Deciphering PI3K biology in health and disease (PhD)
    Research Partner PI: Violeta Serra and Jordi Rodón. Consortium coordinator: Mariona Graupera
    Funding Agency: European Commission
    Duration: 2016-2019

AWARDS

Growth Factors Group

Imagen

Principal Investigator
Joaquín Arribas

Scientific Manager
Cristina Bernadó

Medical Oncologist
César Serrano

Post-Doctoral Fellows
Enrique Javier Arenas
Cristina Bernadó
Beatriz Morancho
Mercedes Nadal
Bhavna Rani
Veronica Rodilla

Masters Student
Rita Casas

Graduate Students
Faiz Bilal
Luis Alfonso Garcia
Irene Rius
Junjie Zhang

Technicians
Marta Escorihuela
Antoni Luque
David Olivares
Jordi Rosell
Ismael Varela

PUBLICATIONS

  1. Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nat Cell Biol. 2018 Jan 22. doi: 10.1038/s41556-017-0021-z. [Epub ahead of print]
  2. Martín-Pérez, R., Yerbes, R., Mora-Molina, R., Cano- González, A., Arribas, J., Mazzone, M., López- Rivas, A.  and Palacios, C. Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.  2017. Oct 3;8(55):93688-93703. doi: 10.18632/oncotarget.21458. eCollection 2017 Nov 7.
  3. Ríos-Luci, C., García-Alonso S., Díaz-Rodríguez E., Nadal-Serrano, M., Arribas, J., Ocaña, A. and Pandiella, A. Deficient lysosomal proteolytic activity underlies resistance to the antibody-drug conjugate trastuzumab-emtansine. Cancer Res Sep 1;77(17):4639-4651. doi: 10.1158/0008-5472.CAN-16-3127. Epub 2017 Jul 7.
  4. Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clin Cancer Res. 2017 Nov 15. 23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.
  5. Pedersen, K.*, Bilal, F.*, Bernadó Morales, C., Salcedo, MT., Macarulla, T., Massó-Vallés, D., Mohan, V., Vivancos, V., Carreras, MJ., Serres, X., Abu-Suboh, M., Balsells, J., Allende, E., Sagi, I., Soucek, L., Tabernero, J., Arribas, J. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene, 2017. Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5.
  6. Byrne, A. T., Alférez, A. G.,Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G. , Gonzalez-Suarez, E. G. , Els Hermans, E, Hidalgo, M., Jarzabek, M., de Jong, S., Jonkers, J., Kemper, K., Lanfrancone, L., Mælandsmo, G. M., Marangoni, E., Marine, J.-C., Enzo Medico, E., Norum, J. H., Palmer, H. G., Peeper, D. S.,Pelicci, P.G., Piris, A., Roman-Roman, S., Rueda, O. M., Seoane, J., Serra, V., Soucek, L., Vanhecke, D., Villanueva, A., Vinolo, E., Bertotti, A., Trusolino, L. (2017) Interrogating open issues in cancer precision medicine with Patient-Derived Xenografts. Nature Rev Cancer Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PROJECTS

  • Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system.
    Breast Cancer Research Foundation (BCRF-17-008)
  • EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts.
    Horizon 2020 call H2020-INFRAIA-2016-2017. 731105
  • COLOSSUS.
    Horizon 2020 call SC1-PM-02-2017. 754923
  • Immunotherapy against p95HER2 positive breast cancer.
    Agència de Gestió d’Ajuts Universitaris i de Recerca AGAUR/Fons Europeus de Desenvolupament Regional (FEDER) 2014-2020. 2016 PROD 00108
  • Preclinical antitumor evaluation of MEN1611 on Breast Cancer PDX models.
    Menarini Riserche S.p.A.
  • Collaboration VHIO and Molecular Partners AG - Preclinical development of MP0274.
    Molecular Partners AG
  • CIBER-ONC Breast Cancer Program.
    Instituto de Salud Carlos III (Subdirección General de Evaluación y Fomento de la Investigación). CB16/12/00449
  • Immunotherapy Against HER2-positive Breast and Gastric Cancers.
    Instituto de Salud Carlos III. PI16/00253
  • Immunoterapia contra tumores de mama apositivos para p95HER2.
    ghD - FERO
  • Novel immunotherapies to treat colorectal and breast cancer.
    BECA FERO
  • Clinical Impact of Intratumor heterogeneity in metastatic breast cancer – CCE.
    European Research Area Net (ERA-NET). Joint Translational Call for Proposals 2014 (JTC). Instituto de Salud Carlos III co-funded by the European Commission/DG Research and Innovation. AC15/00062
  • Establishment of PDX models using patient-derived material from BP29541 phase la/b clinical trial and treatment with RO6958688 (CEA TCB) and CEA TCB2.
    ROCHE GLYCART AG
  • Nuevas Estrategias para Tratar el Cáncer de Mama Positivo para HER2.
    Asociación Española Contra el Cáncer
  • PI3K/AKT/Mtor and RAS/MEK/ERK pathway inhibition in gastrointestinal stromal tumors (GISTs): Identifying novel treatment strategies to overcome resistance to KIT/PDGFRA inhibition in GIST.
  • Immune profiles during breast cancer treatment. Indication of biomarkers of sensitivity/resistance.
    Consorcio de Investigación Biomédica y Oncológica (CIBOT) - Novartis Farmacéutica S.A.
  • Overcoming heterogeneity in gastrointestinal stromal tumors: early detection of resistant subpopulations for tyrosin kinase inhibitor rotation.
    Characterizarion of resistances to ADCs targeting HER2.
    Synthon Biopharmaceuticals B.V.

Mouse Models of Cancer Therapies Group

Imagen

Principal Investigator
Laura Soucek

Staff Scientist
Jonathan Whitfield

Post-Doctoral Fellows
Daniel Massó Vallés
Mariano Zacarías-Fluck

Graduate Students
Toni Jauset González
Sandra Martínez Martín

Technicians
Virginia Castillo Cano
Laia Foradada Felíp
Génesis Martín Fernandez
Meritxell Sánchez Hervás
Erika Serrano del Pozo

PUBLICATIONS

  1. Dang C, Reddy EP, Shokat K, andSoucek L. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer.  2017 Jun 23. doi: 10.1038/nrc.2017.36.
  2. Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivanco A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J and Arribas J. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene.2017 Jun 5. doi: 10.1038/onc.2017.174.
  3. Maltais L, Montagne M, Bédard M, Tremblay C, Soucek L and Lavigne P. Biophysical Characterization of the b-HLH-LZ of ΔMax, an Alternatively Spliced Isoform of Max Found in Tumor Cells: Towards the Validation of a Tumor Suppressor Role for the Max Homodimer. PLoS One. 2017 Mar 28;12(3): e0174413. https://doi.org/10.1371/journal.pone.0174413.
  4. Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front. Cell Dev. Biol., 23 February 2017.
  5. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models. Nat Rev Cancer. 2017 Jan 20. doi: 10.1038/nrc.2016.140.
  6. Beaulieu ME, Jauset T, Massó-Vallés D, Soucek L*and Whitfield JR. Mouse Models in Personalized Cancer Medicine. Chapter 6 of Cancer genetics and Genomics for Personalized Medicine. 2017. ISBN: 9789814669887. Book Chapter. *Corresponding author.

PROJECTS

Ongoing Projects:

  • Grantor: H2020 INFRAIA 2017 Title: EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts
    Role: Co-applicant
    2017-2021
  • Grantor: APC grant to Peptomyc from the Ministry of Economy, Innovation and Competitiveness
    Role: Principal Investigator, Laura Soucek
    2017-2019
  • Grantor: NEOTEC grant to Peptomyc from the Ministry of Economy, Innovation and Competitiveness
    Role: Principal Investigator, Laura Soucek
    2017-2019
  • Grantor: Retos de Colaboraciónfrom the Spanish Ministry of Economy, Industry and Competitiveness
    Title: Preclinical development of Omomyc-CPP as a therapy for cancer treatment
    Role: Principal Investigator, Laura Soucek
    2016-2019
  • Grantor:Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud
    Title: In vivo validation of innovative anti-Myc therapies in glioblastoma
    Role: Principal Investigator, Laura Soucek
    2016-2019
  • Grantor: ERC (European Commission) Consolidator Grant
    Title: Pushing Myc inhibition towards the clinic
    Role: Principal Investigator, Laura Soucek
    2014-2019
  • Grantor: Catalan Agency for Trade and Investment (ACCIÓ)
    Title/Description: Peptomyc received a grant for the project: Pre-clinical development of OmomycCPP:characterization of the immune response
    Role: Principal Investigator, Laura Soucek
    2016-2018

AWARDS

  • Daniel Massó-Valles received one of this year’s Pioneer Awards from the Research Centres of Catalonia (CERCA) Institute, for his PhD entitled Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies. CERCA’s Pioneer Awards recognize up-and-coming research talents who have presented a doctoral thesis with results promising commercial exploitation and technology transfer for societal gain.
  • Peptomyc S.L. was awarded a NEOTEC and an APC grant from the Ministry of Economy, Innovation and Competitiveness, with Laura Soucek as Principal Investigator.
  • Soucek was selected by EIT Health as a Role Model for the project Empowering Women Entrepreneurship in Health Innovation(WE Health) aiming to enhance the participation of women in health innovation and entrepreneurship activities. For more information: http://www.we.eithealth.eu/en/role-models.

Tumor Biomarkers Group

Imagen

Principal Investigator
Josep Villanueva

Post-Doctoral Fellows
Juan Manuel Duran
Mercè Juliachs
Olga Méndez
Nathalie Meo-Evoli

Graduate Student
Mireia Pujals

Technicians
Ana Matres
Candida Salvans

PROJECTS

  • Diagnostic and Therapeutic implications of extracellular HMGA1 in Breast Cancer
    Agency : Susan G Komen
    Duration: 15/09/2015 - 15/09/2017
    Principal Investigator: Josep Villanueva
  • Characterization of the role of HMGA1 as a mediator of tumor progression in breast cáncer
    Agency: Instituto Carlos III
    Duration: 1/01/2016 - 31/12/2018
    Principal Investigator: Josep Villanueva